PPARγ insufficiency enhances osteogenesis through osteoblast formation from bone marrow progenitors

Journal of Clinical Investigation

Volumn 113, Issue 6, 2004, Pages 846-855

  Akune, Toru ^a   Ohba, Shinsuke ^a   Kamekura, Satoru ^a   Yamaguchi, Masayuki ^a   Chung, Ung Il ^a   Kubota, Naoto ^a   Terauchi, Yasuo ^a   Harada, Yoshifumi ^b   Azuma, Yoshiaki ^b   Nakamura, Kozo ^a   Kadowaki, Takashi ^a   Kawaguchi, Hiroshi ^a  

^a UNIVERSITY OF TOKYO   (Japan)

^b TEIJIN LTD   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

INSULIN; LEPTIN; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR GAMMA; CELL RECEPTOR; TRANSCRIPTION FACTOR;

ADIPOCYTE; ADIPOSE TISSUE; AGING; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL TISSUE; ARTICLE; BONE DEVELOPMENT; BONE MARROW CELL; BONE MASS; BONE METABOLISM; CELL CULTURE; CELL DIFFERENTIATION; CONTROLLED STUDY; EMBRYO; FEMALE; HETEROZYGOSITY; IN VIVO STUDY; MALE; MOUSE; NONHUMAN; NUCLEOTIDE SEQUENCE; OSTEOBLAST; OSTEOCLAST; OVARIECTOMY; PRIORITY JOURNAL; PROTEIN FUNCTION; STEM CELL; ANIMAL; BONE; FEMUR; GENE TARGETING; GENETICS; METABOLISM; OVARY; PHYSIOLOGY; RADIOGRAPHY; TIBIA;

ANIMALS; BONE AND BONES; BONE MARROW CELLS; FEMALE; FEMUR; GENE TARGETING; MICE; OSTEOBLASTS; OSTEOGENESIS; OVARIECTOMY; OVARY; RECEPTORS, CYTOPLASMIC AND NUCLEAR; STEM CELLS; TIBIA; TRANSCRIPTION FACTORS;

EID: 2142652189     PISSN: 00219738     EISSN: None     Source Type: Journal    
DOI: 10.1172/JCI200419900     Document Type: Article

References (57)

1. Beresford, J.N. 1989. Osteogenic stem cells and the stromal system of bone and marrow. Clin. Orthop. 240:270-280.
2. Pittenger, M.F., et al. 1999. Multilineage potential of adult human mesenchymal stem cells. Science. 284:143-147.
3. Bennett, J.H., Joyner, C.J., Triffitt, J.T., and Owen, M.E. 1991. Adipocytic cells cultured from marrow have osteogenic potential. J. Cell Sci. 99:131-139.
4. Nuttall, M.E., Patton, A.J., Olivera, D.L., Nadeau, D.P., and Gowen, M. 1998. Human trabecular bone cells are able to express both osteoblastic and adipocytic phenotype: implications for osteopenic disorders. J. Bone Miner. Res. 13:371-382.
5. Park, S.R., Oreffo, R.O., and Triffitt, J.T. 1999. Interconversion potential of cloned human marrow adipocytes in vitro. Bone. 24:549-554.
6. Beresford, J.N., Bennett, J.H., Devlin, C., Leboy, P.S., and Owen, M.E. 1992. Evidence for an inverse relationship between the differentiation of adipocytic and osteogenic cells in rat marrow stromal cell cultures. J. Cell Sci. 102:341-351.
7. Meunier, P., Aaron, J., Edouard, C., and Vignon, G. 1971. Osteoporosis and the replacement of cell populations of the marrow by adipose tissue. A quantitative study of 84 iliac bone biopsies. Clin. Orthop. 80:147-154.
8. Burkhardt, R., et al. 1987. Changes in trabecular bone, hematopoiesis and bone marrow vessels in aplastic anemia, primary osteoporosis, and old age: a comparative histomorphometric study. Bone. 8:157-164.
9. Rozman, C., et al. 1989. Age-related variations of fat tissue fraction in normal human bone marrow depend both on size and number of adipocytes: a stereological study. Exp. Hematol. 17:34-37.
10. Jilka, R.L., Weinstein, R.S., Takahashi, K., Parfitt, A.M., and Manolagas, S.C. 1996. Linkage of decreased bone mass with impaired osteoblastogenesis in a murine model of accelerated senescence. J. Clin. Invest. 97:1732-1740.
11. Ducy, P., et al. 2000. Leptin inhibits bone formation through a hypothalamic relay: a central control of bone mass. Cell. 100:197-207.
12. Sabatakos, G., et al. 2000. Overexpression of DeltaFosB transcription factor(s) increases bone formation and inhibits adipogenesis. Nat. Med. 6:985-990.
13. Takeda, S., et al. 2002. Leptin regulates bone formation via the sympathetic nervous system. Cell. 111:305-317.
14. Takeuchi, Y., et al. 2002. Interleukin-11 as a stimulatory factor for bone formation prevents bone loss with advancing age in mice. J. Biol. Chem. 277:49011-49018.
15. Kodama, Y., et al. 1998. Reduced expression of interleukin-11 in bone marrow stromal cells of senescence-accelerated mice (SAMP6): relationship to osteopenia with enhanced adipogenesis. J. Bone Miner. Res. 13:1370-1377.
16. Rosen, E.D., Walkey, C.J., Puigserver, P., and Spiegelman, B.M. 2000. Transcriptional regulation of adipogenesis. Genes Dev. 14:1293-1307.
17. Rosen, E.D., and Spiegelman, B.M. 2001. PPARγ: a nuclear regulator of metabolism, differentiation, and cell growth. J. Biol. Chem. 12:37731-37734.
18. Kersten, S., Desvergne, B., and Wahli, W. 2000. Roles of PPARs in health and disease. Nature. 405:421-424.
19. Mangelsdorf, D.J., and Evans, R.M. 1995. The RXR heterodimers and orphan receptors. Cell. 83:841-850.
20. Tontonoz, P., Hu, E., and Spiegelman, B.M. 1994. Stimulation of adipogenesis in fibroblasts by PPAR γ 2, a lipid-activated transcription factor. Cell. 79:1147-1156.
21. Barak, Y., et al. 1999. PPAR γ is required for placental, cardiac, and adipose tissue development. Mol. Cell. 4:585-595.
22. Kubota, N., et al. 1999. PPAR γ mediates high-far diet-induced adipocyte hypertrophy and insulin resistance. Mol. Cell. 4:597-609.
23. Rosen, E.D., et al. 1999. PPAR γ is required for the differentiation of adipose tissue in vivo and in vitro. Mol. Cell. 4:611-617.
24. Kadowaki, T. 2000. Insights into insulin resistance and type 2 diabetes from knockout mouse models. J. Clin. Invest. 106:459-465.
25. Bradley, A. 1987. Production and analysis of chimaeric mice. In Teratocarcinomas and embryonic stem cells. E.J. Robertson, editor. IRL Press. Oxford, United Kingdom. 113-151.
26. Keller, G.M. 1995. In vitro differentiation of embryonic stem cells. Curr. Opin. Cell Biol. 7:862-869.
27. Akune, T., et al. 2002. Insulin receptor substrate-2 maintains predominance of anabolic function over catabolic function of osteoblasts. J. Cell Biol. 159:147-156.
28. Kobayashi, K., et al. 2000. Tumor necrosis factor α stimulates osteoclast differentiation by a mechanism independent of the ODF/RANKL-RANK interaction. J. Exp. Med. 191:275-286.
29. Yamauchi, T., et al. 2001. The mechanisms by which both heterozygous peroxisome proliferator-activated receptor γ(PPARγ) deficiency and PPARgamma agonist improve insulin resistance. J. Biol. Chem. 276:41245-41254.
30. Thomas, D.M., Hards, D.K., Rogers, S.D., Ng, K.W., and Best, J.D., 1997. Insulin and bone, clinical and scientific view. Endocrinology and Metabolism. 4:5-17.
31. Takeda, S., and Karsenty, G. 2001. Central control of bone formation. J. Bone Miner. Metab. 19:195-198.
32. Tanaka, T., Yoshida, N., Kishimoto, T., and Akira, S. 1997. Defective adipocyte differentiation in mice lacking the C/EBPβ and/or C/EBPδ gene. EMBO J. 16:7432-7443.
33. Wu, Z., et al. 1999. Cross-regulation of C/EBPα and PPAR γ controls the transcriptional pathway of adipogenesis and insulin sensitivity. Mol. Cell. 3:151-158.
34. Karsenty, G. 2001. Minireview: transcriptional control of osteoblast differentiation. Endocrinology. 142:2731-2733.
35. Nakashima, K., et al. 2002. The novel zinc finger-containing transcription factor osterix is required for osteoblast differentiation and bone formation. Cell. 108:17-29.
36. Patel, M. S., and Karsenty, G. 2002. Regulation of bone formation and vision by LRP5. N. Engl. J. Med. 346:1572-1574.
37. Suda, T., et al. 1999. Modulation of osteoclast differentiation and function by the new members of the tumor necrosis factor receptor and ligand families. Endocr. Rev. 20:345-357.
38. Lecka-Czernik, B., et al. 1999. Inhibition of Osf2/Cbfa1 expression and terminal osteoblast differentiation by PPARγ2. J. Cell. Biochem. 74:357-371.
39. Ricote, M., Li, A.C., Willson, T.M., Kelly, C.J., and Glass, C.K. 1998. The peroxisome proliferator-activated receptor-γ is a negative regulator of macrophage activation. Nature. 391:79-82.
40. Tolon, R.M., Castillo, A.I., and Aranda, A. 1998. Activation of the prolactin gene by peroxisome proliferator-activated receptor-α appears to be DNA binding-independent. J. Biol. Chem. 273:26652-26661.
41. Benson, S., Wu, J., Padmanabhan, S., Kurtz, T.W., and Pershadsingh, H.A. 2000. Peroxisome proliferator-activated receptor (PPAR)-γ expression in human vascular smooth muscle cells: inhibition of growth, migration, and c-fos expression by the peroxisome proliferator-activated receptor (PPAR)-γ activator troglitazone. Am. J. Hypertens. 13:74-82.
42. Alliston, T., Choy, L., Ducy, P., Karsenty, G., and Derynck, R. 2001. TGF-β-induced repression of CBFA1 by Smad3 decreases cbfa1 and osteocalcin expression and inhibits osteoblast differentiation. EMBO J. 20:2254-2272.
43. Botton, A.J., Frederick, J.P., Datto, M.B., Wang K.F., and Weinstein, R.S. 2001. The loss of Smad3 results in a lower rate of bone formation and osteopenia through dysregulation of osteoblast differentiation and apoptosis. J. Bone Miner. Res. 16:1754-1764.
44. Fu, M., et al. 2001. Peroxisome proliferator-activated receptor γ inhibits transforming growth factor beta-induced connective tissue growth factor expression in human aortic smooth muscle cells by interfering with Smad3. J. Biol. Chem. 276:45888-45894.
45. Ross, S.E., et al. 2000. Inhibition of adipogenesis by Wnt signaling. Science. 289:950-953.
46. Bennett, C.N., et al. 2002. Regulation of Wnt signaling during adipogenesis. J. Biol. Chem. 277:30998-31004.
47. Bain, G., Muller, T., Wang, X., and Papkoff, J. 2003. Activated β-catenin induces osteoblast differentiation of C3H10T1/2 cells and participates in BMP2 mediated signal transduction. Biochem. Biophys. Res. Commun. 301:84-91.
48. Smith, E., Coetzee, G.A., and Frenkel, B. 2002. Glucocorticoids inhibit cell cycle progression in differentiating osteoblasts via glycogen synthase kinase-3β. J. Biol. Chem. 277:18191-18197.
49. Garcia, T., et al. 2002. Behavior of osteoblast, adipocyte, and myoblast markers in genome-wide expression analysis of mouse calvaria primary osteoblasts in vitro. Bone. 31:205-211.
50. Krakauer, J.C., McKenna, M.J., Rao, D.S., and Whitehouse, F.W. 1997. Bone mineral density in diabetes. Diabetes Care. 20:1339-1340.
51. Piepkorn, B., et al. 1997. Bone mineral density and bone metabolism in diabetes mellitus. Horm. Metab. Res. 29:584-591.
52. Ogata, N., et al. 2000. Insulin receptor substrate-1 in osteoblast is indispensable for maintaining bone turnover. J. Clin. Invest. 105:935-943.
53. Elmquist, J.K., Elias, C.F., and Saper, C.B. 1999. From lesions to leptin: hypothalamic control of food intake and body weight. Neuron. 22:221-232.
54. Kallen, C.B., and Lazar, M.A. 1996. Antidiabetic thiazolidinediones inhibit leptin (ob) gene expression in 3T3-L1 adipocytes. Proc. Natl. Acad. Sci. U. S. A. 93:5793-5796.
55. Hollenberg, A.N., et al. 1997. Functional antagonism between CCAAT/enhancer binding protein-α and peroxisome proliferator-activated receptor-α on the leptin promoter. J. Biol. Chem. 272:5283-5290.
56. Ogawa, S., et al. 1999. Association of bone mineral density with a polymorphism of the peroxisome proliferator-activated receptor γ gene: PPARγ expression in osteoblasts. Biochem. Biophys. Res. Commun. 260:122-126.
57. Nguyen, T.V., Blangero, J., and Eisman, J.A. 2000. Genetic epidemiological approaches to the search for osteoporosis genes. J. Bone Miner. Res. 15:392-401.